Lipids/Obesity/Nutrition
24 cases on statin and non-statin lipid-lowering choices, GLP-1/GIP therapy for obesity, perioperative and adherence-driven decisions, and nutrition support in critical illness and malnutrition — choose a case below to open its full multi-voice debate.
A 58-year-old man with a borderline pooled-cohort risk score and a calcium score of zero, weighed against a brother's heart attack four months ago — whether a single clean scan should outrank a family history the scan cannot fully see.
A statin-intolerant woman with prior myocardial infarction and persistent LDL elevation on ezetimibe, choosing between a more potent injectable PCSK9 inhibitor and a less potent, better-tolerated oral bempedoic acid.
A 34-year-old man with genetically confirmed heterozygous familial hypercholesterolemia and a non-obstructive coronary lesion numerically meets the criteria for LDL apheresis — whether meeting the threshold on paper means his pharmacologic options are actually exhausted.
A 46-year-old woman with a family history of early coronary disease and normal LDL asks whether to check her lipoprotein(a) — a heritable risk factor with no FDA-approved targeted therapy yet, testable today for reasons that have nothing to do with a future drug.
A man with established coronary disease and a documented history of quietly lapsing on a biweekly PCSK9 injection weighs a twice-yearly siRNA against monoclonal antibodies with proven, but harder-to-sustain, outcomes benefit.
A woman with elevated cardiovascular risk and pre-diabetic features weighs a real, dose-dependent statin-associated diabetes signal against a cardiovascular benefit both physicians agree clearly outweighs it — and debates what that agreement should still change about how she's monitored.
A woman with familial hypercholesterolemia planning a pregnancy asks whether to continue her statin through conception, now that the FDA has removed the drug class's pregnancy contraindication — and how much that label change should actually settle for a patient with her specific risk.
A non-diabetic man with established coronary disease and obesity is offered semaglutide for cardiovascular risk reduction — a role the SELECT trial established independent of how much weight he actually loses.
A 38-year-old woman with obesity and no diabetes asks whether semaglutide and tirzepatide are 'basically the same drug' — a question the SURMOUNT-5 head-to-head trial has since given a real, quantified answer to.
A woman who reached her target weight on semaglutide wants to stop — a request that runs directly into the trial data on what happens after GLP-1 therapy is discontinued.
A patient on compounded tirzepatide, started during the real national shortage, now faces a closing legal and regulatory pathway — and a cost gap that made the compounded product her only affordable option in the first place.
A patient a year into meaningful weight loss on semaglutide faces a recommended preoperative hold for an elective procedure — and genuine fear that any interruption will undo his progress the way sustained discontinuation has been shown to.
A 71-year-old woman losing weight steadily on semaglutide is also losing a meaningful share of it as muscle, not fat — a real, underexplained cost of rapid GLP-1-driven weight loss in an older patient who cannot afford to lose strength.
A woman with obesity, untreated depression, and eating she describes as stress- and boredom-driven rather than hunger-driven is offered naltrexone-bupropion over a more potent GLP-1 agonist — a choice built on mechanism fit, not the biggest topline weight-loss number.
A woman with treated hypertension and an uncovered weight-loss drug benefit is offered phentermine-topiramate over a GLP-1 agonist — a choice driven openly by affordability, with real cardiovascular monitoring built in given phentermine's sympathomimetic effects.
A woman with a recently recurrent binge-eating disorder asks about weight-loss medication — a request that runs directly into the real risk that appetite-altering pharmacotherapy could destabilize a still-fragile remission.
A woman at maximum-dose semaglutide for nine months has lost only 6% of her body weight, well below the drug's typical result — a genuine partial-response pattern with no single, trial-validated next step.
A man asks for retatrutide by name after reading about its Phase 3 weight-loss results — a drug with no FDA approval, no submitted application, and no legitimate source outside an actively enrolling outcomes trial.
A woman with obesity and a family history of 'thyroid cancer,' unspecified histology, needs a real workup — not a reflexive GLP-1 exclusion or a reflexive dismissal — before her boxed-warning eligibility can actually be determined.
A critically ill man on downtrending norepinephrine support needs a nutrition decision that neither reflexively follows EPaNIC's case against early parenteral nutrition nor ignores the real bowel-perfusion risk his vasopressor dose still carries.
A severely malnourished man with multiple stacked refeeding-syndrome risk factors needs nutrition restarted — the real, current debate is whether traditional ultra-conservative caloric advancement is actually the safest path, or an outdated default that itself carries a cost.
A woman three years past Roux-en-Y gastric bypass presents with fatigue, neuropathy, and severe iron deficiency — deficiencies standard prophylactic supplementation should have prevented, raising an urgent repletion question and an honest adherence conversation.
A man taking a marketed 'metabolic health' supplement regimen at doses far above any established requirement presents with a frankly toxic vitamin D level and early hypercalcemia — a real cost of megadosing fat-soluble vitamins that accumulate rather than clear.
A frail woman with advanced dementia, metastatic cancer, and severe malnutrition is offered a choice her family frames as 'the feeding tube or giving up' — a false binary the actual evidence on tube feeding in advanced dementia doesn't support.